MayTech Global Investments LLC Acquires 21,509 Shares of DexCom, Inc. (NASDAQ:DXCM)

MayTech Global Investments LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 280,766 shares of the medical device company's stock after buying an additional 21,509 shares during the period. DexCom accounts for about 2.6% of MayTech Global Investments LLC's portfolio, making the stock its 17th largest position. MayTech Global Investments LLC owned 0.07% of DexCom worth $21,835,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Congress Asset Management Co. raised its position in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of DexCom by 2,226.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock valued at $18,085,000 after purchasing an additional 222,548 shares in the last quarter. Proficio Capital Partners LLC bought a new position in shares of DexCom during the fourth quarter valued at approximately $5,812,000. Mitsubishi UFJ Asset Management UK Ltd. increased its holdings in DexCom by 500.0% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 6,000 shares of the medical device company's stock valued at $467,000 after buying an additional 5,000 shares during the period. Finally, Merit Financial Group LLC bought a new position in DexCom in the fourth quarter worth approximately $228,000. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at $22,063,918.86. This represents a 4.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. This trade represents a 8.03% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 66,926 shares of company stock worth $4,734,384. Corporate insiders own 0.32% of the company's stock.

DexCom Trading Up 0.4%

NASDAQ DXCM opened at $85.05 on Tuesday. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $132.26. The stock has a market capitalization of $33.35 billion, a P/E ratio of 59.48, a PEG ratio of 2.30 and a beta of 1.43. The firm's 50-day moving average is $71.14 and its two-hundred day moving average is $77.30. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the firm posted $0.32 earnings per share. The company's quarterly revenue was up 12.5% compared to the same quarter last year. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Citigroup upped their price objective on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Piper Sandler cut their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and increased their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.11.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.